FKBP51 and FKBP52 in signaling and disease

Trends in Endocrinology and Metabolism

Volumn 22, Issue 12, 2011, Pages 481-490

  Storer, Cheryl L ^a   Dickey, Chad A ^b   Galigniana, Mario D ^c   Rein, Theo ^d   Cox, Marc B ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; MULTIPROTEIN COMPLEX; PROGESTERONE RECEPTOR; PROTEIN FKBP51; PROTEIN FKBP52; PROTEIN KINASE B; RECEPTOR CHAPERONE COMPLEX; REGULATOR PROTEIN; STEROID HORMONE; STEROID RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; BIPOLAR DISORDER; BREAST CARCINOGENESIS; BREAST TUMOR; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; DEPRESSION; DISEASE ASSOCIATION; DRUG TARGETING; GENITAL SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; MENTAL STRESS; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TACROLIMUS BINDING PROTEINS;

EID: 82555167019     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.08.001     Document Type: Review

References (99)

1. Sanchez E.R. Hsp56: a novel heat shock protein associated with untransformed steroid receptor complexes. J. Biol. Chem. 1990, 265:22067-22070.
2. Smith D.F., et al. Purification of unactivated progesterone receptor and identification of novel receptor-associated proteins. J. Biol. Chem. 1990, 265:3996-4003.
3. Pirkl F., Buchner J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J. Mol. Biol. 2001, 308:795-806.
4. Cheung-Flynn J., et al. FKBP co-chaperones in steroid receptor complexes. Cell Stress Proteins 2007, 281-312. Springer. S.K. Calderwood (Ed.).
5. Riggs D.L., et al. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 2003, 22:1158-1167.
6. Tranguch S., et al. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14326-14331.
7. Cheung-Flynn J., et al. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 2005, 19:1654-1666.
8. Cox M.B., Smith D.F. Functions of the Hsp90-binding FKBP immunophilins. The Networking of Chaperones by Cochaperones 2006, 13-25. Landes Bioscience. G.L. Blatch (Ed.).
9. Riggs D.L., et al. Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Mol. Cell Biol. 2007, 27:8658-8669.
10. Sinars C.R., et al. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:868-873.
11. Miyata Y., et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14500-14505.
12. Cox M.B., et al. FK506-binding protein 52 phosphorylation: a potential mechanism for regulating steroid hormone receptor activity. Mol. Endocrinol. 2007, 21:2956-2967.
13. Barent R.L., et al. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol. Endocrinol. 1998, 12:342-354.
14. Silverstein A.M., et al. Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein. J. Biol. Chem. 1999, 274:36980-36986.
15. Banerjee A., et al. Control of glucocorticoid and progesterone receptor subcellular localization by the ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat proteins. Biochemistry 2008, 47:10471-10480.
16. Witchel S.F., DeFranco D.B. Mechanisms of disease: regulation of glucocorticoid and receptor levels - impact on the metabolic syndrome. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:621-631.
17. Galigniana M.D., et al. Role of molecular chaperones and TPR-domain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore. Nucleus 2010, 1:299-308.
18. Galigniana M.D., et al. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem. 2001, 276:14884-14889.
19. Davies T.H., et al. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J. Biol. Chem. 2002, 277:4597-4600.
20. Wochnik G.M., et al. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem. 2005, 280:4609-4616.
21. Piwien Pilipuk G., et al. Evidence for NL1-independent nuclear translocation of the mineralocorticoid receptor. Biochemistry 2007, 46:1389-1397.
22. Gallo L.I., et al. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity. Biochemistry 2007, 46:14044-14057.
23. Galigniana M.D., et al. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol. Cell Biol. 2010, 30:1285-1298.
24. Harrell J.M., et al. Evidence for glucocorticoid receptor transport on microtubules by dynein. J. Biol. Chem. 2004, 279:54647-54654.
25. Galigniana M.D., et al. Binding of hsp90-associated immunophilins to cytoplasmic dynein: direct binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein interaction domain. Biochemistry 2002, 41:13602-13610.
26. Galigniana M.D., et al. Retrograde transport of the glucocorticoid receptor in neurites requires dynamic assembly of complexes with the protein chaperone hsp90 and is linked to the CHIP component of the machinery for proteasomal degradation. Brain Res. Mol. Brain Res. 2004, 123:27-36.
27. Galigniana M.D., et al. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J. Biol. Chem. 2004, 279:22483-22489.
28. Pratt W.B. Transformation of glucocorticoid and progesterone receptors to the DNA-binding state. J. Cell. Biochem. 1987, 35:51-68.
29. Schaaf M.J., Cidlowski J.A. Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity. Mol. Cell. Biol. 2003, 23:1922-1934.
30. Echeverria P.C., et al. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol. Cell. Biol. 2009, 29:4788-4797.
31. Yong W., et al. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 2007, 282:5026-5036.
32. Hong J., et al. Deficiency of co-chaperone immunophilin FKBP52 compromises sperm fertilizing capacity. Reproduction 2007, 133:395-403.
33. Tranguch S., et al. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J. Clin. Invest. 2007, 117:1824-1834.
34. Yang Z., et al. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor A isoform. Mol. Endocrinol. 2006, 20:2682-2694.
35. Hirota Y., et al. Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15577-15582.
36. Hirota Y., et al. Deficiency of immunophilin FKBP52 promotes endometriosis. Am. J. Pathol. 2008, 173:1747-1757.
37. Chambraud B., et al. A role for FKBP52 in Tau protein function. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2658-2663.
38. Jinwal U.K., et al. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J. Neurosci. 2010, 30:591-599.
39. Stechschulte L.A., Sanchez E.R. FKBP51 - a selective modulator of glucocorticoid and androgen sensitivity. Curr. Opin. Pharmacol. 2011, 11:332-337.
40. O'Malley K.J., et al. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate 2009, 69:1716-1723.
41. Periyasamy S., et al. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 2007, 148:4716-4726.
42. Ni L., et al. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol. Cell. Biol. 2010, 30:1243-1253.
43. Periyasamy S., et al. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010, 29:1691-1701.
44. Schålke J.P., et al. Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors. PLoS ONE 2010, 5:e11717.
45. Mukaide H., et al. FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma. Cancer Invest. 2008, 26:385-390.
46. Rees-Unwin K.S., et al. Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br. J. Haematol. 2007, 139:559-567.
47. Avellino R., et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005, 106:1400-1406.
48. Romano S., et al. FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med. Chem. 2010, 10:651-656.
49. Pei H., et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
50. Warrier M., et al. Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. Endocrinology 2010, 151:3225-3236.
51. Lin J.F., et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer 2007, 121:2596-2605.
52. De Leon J.T., et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11878-11883.
53. Sivils J.C., et al. Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52). Curr. Opin. Pharmacol. 2011, 11:314-319.
54. De Kloet E.R., et al. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
55. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
56. Binder E.B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
57. Kirchheiner J., et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9:841-846.
58. *D: strengths, limitations, and results. Psychiatr. Serv. 2009, 60:1446-1457.
59. *D) cohort. Biol. Psychiatry 2008, 63:1103-1110.
60. Zou Y.F., et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 2010, 484:56-61.
61. Velders F.P., et al. Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approach. Psychoneuroendocrinology 2011, 36:1053-1061.
62. Willour V.L., et al. Family-based association of FKBP5 in bipolar disorder. Mol. Psychiatry 2008, 14:261-268.
63. Lavebratt C., et al. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J. Affect. Disord. 2010, 125:249-255.
64. Brent D., et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 2010, 167:190-197.
65. Roy A., et al. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 2010, 35:1674-1683.
66. Supriyanto I., et al. Association of FKBP5 gene haplotypes with completed suicide in the Japanese population. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:252-256.
67. Shibuya N., et al. Association study between a functional polymorphism of FK506-binding protein 51 (FKBP5) gene and personality traits in healthy subjects. Neurosci. Lett. 2010, 485:194-197.
68. Ising M., et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neurosci. 2008, 28:389-398.
69. Koenen K.C., et al. Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol. Psychiatry 2005, 10:1058-1059.
70. Ozer E.J., et al. Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis. Psychol. Bull. 2003, 129:52-73.
71. Yehuda R., et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol. Psychiatry 2009, 66:708-711.
72. Binder E.B., et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. J. Am. Med. Assoc. 2008, 299:1291-1305.
73. Koenen K.C., Uddin M. FKBP5 polymorphisms modify the effects of childhood trauma. Neuropsychopharmacology 2010, 35:1623-1624.
74. Xie P., et al. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology 2010, 35:1684-1692.
75. Zimmermann, P., et al. Interaction of variants in the FKBP5 gene and adverse life events in predicting the first depression onset: results from a ten-year prospective community study. Am. J. Psychiatry, in press.
76. Lee R.S., et al. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 2010, 151:4332-4343.
77. Matsushita R., et al. Enhanced expression of mRNA for FK506-binding protein 5 in bone marrow CD34 positive cells in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2010, 28:87-90.
78. Jiang W., et al. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 2008, 10:235-243.
79. Park J., et al. Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens. Mol. Cell Endocrinol. 2007, 278:7-17.
80. Baker R.G., et al. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
81. Hayden M.S., Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011, 21:223-244.
82. Nakamura N., et al. Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res. 2006, 13:169-183.
83. Holownia A., et al. Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy. Eur. J. Med. Res. 2009, 14(Suppl. 4):108-111.
84. Imai A., et al. Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51. Eur. J. Immunol. 2007, 37:1730-1738.
85. Baughman G., et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol. Cell. Biol. 1995, 15:4395-4402.
86. Weiwad M., et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006, 45:15776-15784.
87. Li T.K., et al. Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin 1692. J. Cell. Biochem. 2002, 84:460-471.
88. Smith D.F., et al. Reconstitution of progesterone receptor with heat shock proteins. Mol. Endocrinol. 1990, 4:1704-1711.
89. Smith D.F. Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol. Endocrinol. 1993, 7:1418-1429.
90. Li J., et al. Mixed Hsp90-cochaperone complexes are important for the progression of the reaction cycle. Nat. Struct. Mol. Biol. 2011, 18:61-66.
91. Hildenbrand Z.L., et al. Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins. Oncotarget 2011, 2:45-58.
92. Dickey C.A., et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 2007, 117:648-658.
93. Waza M., et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 2005, 11:1088-1095.
94. Sittler A., et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1307-1315.
95. Auluck P.K., et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
96. Kraemer B.C., et al. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum. Mol. Genet. 2006, 15:1483-1496.
97. Chambraud B., et al. The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J. 2007, 21:2787-2797.
98. Elbi C., et al. A novel in situ assay for the identification and characterization of soluble nuclear mobility factors. Sci. STKE 2004, 2004:pl10.
99. Galas M.C., et al. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J. Biol. Chem. 2006, 281:19296-19304.